AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36200919 — intervention group
Group type: EXPERIMENTAL
Intervention: PNT (Polanight‐22%)
Number of subjects: 10
Study 34157027 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 128
Study 34157027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 32187781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 39
Study 36055978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral ondansetron (0.33 mg twice daily)
Number of subjects: 95
Study 36055978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 33814891 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance Adapted for individuals with Impaired Mobility (GLB‐AIM), a 12‐month intensive lifestyle intervention
Number of subjects: 31
Study 36036121 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 2 mg/(kg·day) (maximum 60 mg) for 4 weeks
Number of subjects: 89
Study 36036121 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 2 mg/(kg·day) (maximum 60 mg) for 6 weeks
Number of subjects: 89
Study 36036121 — intervention group
Group type: COMPARATOR
Intervention: Prednisone treatment for 4 weeks
Number of subjects: 89
Study 36036121 — intervention group
Group type: COMPARATOR
Intervention: Prednisone treatment for 6 weeks
Number of subjects: 89
Study 32050728 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial measurements using gyroscope and accelerometer from smartphones and wearable IMUs
Number of subjects: 86
Study 36004653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (5, 10, and 15 mg)
Number of subjects: 0
Study 36004653 — intervention group
Group type: COMPARATOR
Intervention: Tirzepatide
Number of subjects: 0
Study 33361493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle Kinesio Taping (KT)
Number of subjects: 28
Study 36193438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-movement speed training (0.75-0.96 m/s, approximately 60% 1RM)
Number of subjects: 22
Study 36193438 — intervention group
Group type: EXPERIMENTAL
Intervention: High-movement speed training (1.03-1.20 m/s, approximately 40% 1RM)
Number of subjects: 22
Study 34340194 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient deterioration simulation using inattentional blindness (PDS‐IB)
Number of subjects: 91
Study 34340194 — intervention group
Group type: COMPARATOR
Intervention: Simple patient deterioration simulation (control)
Number of subjects: 91
Study 33124994 — intervention group
Group type: EXPERIMENTAL
Intervention: Web application with personalized avatars for community immunity visualization
Number of subjects: 110
Study 33124994 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative design process involving multiple users
Number of subjects: 110
Study 33124994 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of users’ emotional responses during design process
Number of subjects: 110
Study 33124994 — intervention group
Group type: COMPARATOR
Intervention: Future randomized controlled trial
Number of subjects: 110
Study 35634869 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training (tilt training and aerobic exercise)
Number of subjects: 50
Study 35634869 — intervention group
Group type: COMPARATOR
Intervention: Standard care with home tilt training
Number of subjects: 50
Study 35634869 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training
Number of subjects: 50
Study 32986116 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypassing healthcare facilities
Number of subjects: 311
Study 32986116 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician referral
Number of subjects: 311
Study 32986116 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal choice
Number of subjects: 311
Study 32986116 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation of HMO
Number of subjects: 311
Study 32986116 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of friends/family/colleagues
Number of subjects: 311
Study 32986116 — intervention group
Group type: EXPERIMENTAL
Intervention: Travel time to farther hospitals
Number of subjects: 311
Study 32986116 — intervention group
Group type: EXPERIMENTAL
Intervention: Travel cost to farther hospitals
Number of subjects: 311
Study 32986116 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational status
Number of subjects: 311
Study 32291277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0
Study 32291277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0
Study 32291277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (10, 15 mg)
Number of subjects: 0
Study 32291277 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study 32291277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35462384 — intervention group
Group type: EXPERIMENTAL
Intervention: Concord Centre for Mental Health‐Revised
Number of subjects: 188
Study 35462384 — intervention group
Group type: EXPERIMENTAL
Intervention: Concord Centre for Mental Health‐Original
Number of subjects: 188
Study 35462384 — intervention group
Group type: COMPARATOR
Intervention: Generic information package on depression
Number of subjects: 188
Study 34758761 — intervention group
Group type: EXPERIMENTAL
Intervention: OBEST application combined with standard care
Number of subjects: 77
Study 34758761 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 77
Study 35410292 — intervention group
Group type: EXPERIMENTAL
Intervention: Jockey Club Holistic Support Project for Elderly Mental Wellness (JC JoyAge) model
Number of subjects: 0
Study 35410292 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 0
Study 35143800 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg weekly
Number of subjects: 216
Study 35143800 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil 1.5 g twice daily
Number of subjects: 216
Study 35143800 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 25 mg weekly (for those who switched treatment)
Number of subjects: 216
Study 35143800 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil 1.5 g twice daily (for those who switched treatment)
Number of subjects: 216
Study 34383954 — intervention group
Group type: EXPERIMENTAL
Intervention: verinurad + allopurinol (12, 7.5 or 3 mg)
Number of subjects: 725
Study 35627776 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of consensual efficacy findings
Number of subjects: 259
Study 35627776 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported expertise in helmet legislation
Number of subjects: 259
Study 35627776 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to results showing a lack of evidence of efficacy
Number of subjects: 259
Study 35627776 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' helmet use
Number of subjects: 259
Study 33951086 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeLab educational intervention
Number of subjects: 2929
Study 32617631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral opioid rescue medication (hydromorphone) in Cohort 1 (C1)
Number of subjects: 214
Study 32617631 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) with piritramide in Cohort 2 (C2)
Number of subjects: 214
Study 32617631 — intervention group
Group type: EXPERIMENTAL
Intervention: Total opioid consumption in Cohort 1 (C1)
Number of subjects: 214
Study 32617631 — intervention group
Group type: COMPARATOR
Intervention: Total opioid consumption in Cohort 2 (C2)
Number of subjects: 214
Study 32617631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue opioids in Cohort 1 (C1)
Number of subjects: 214
Study 32617631 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic analgesia opioid use in Cohort 1 (C1)
Number of subjects: 214
Study 32617631 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional outcome and patient satisfaction with pain management
Number of subjects: 214
Study 32617631 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of mobilization, sleep, frequency of nausea and vomiting, general satisfaction with pain management
Number of subjects: 214
Study 35551086 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE) followed by further chemotherapy if indicated
Number of subjects: 50
Study 35551086 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (standard of care)
Number of subjects: 50
Study 34374162 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and counselling about prenatal genetic tests
Number of subjects: 210
Study 32497956 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitions about Smartphone Use Questionnaire (MSUQ) factors
Number of subjects: 701
Study 36137981 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUShape 25/0.06
Number of subjects: 50
Study 36137981 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUShape 30/0.06
Number of subjects: 50
Study 36137981 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortex Blue 25/0.06
Number of subjects: 50
Study 36137981 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortex Blue 30/0.06
Number of subjects: 50
Study 36137981 — intervention group
Group type: COMPARATOR
Intervention: Positive Control
Number of subjects: 50
Study 36137981 — intervention group
Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 50
Study 33774192 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution with conventional cementation system (etch‐and‐rinse adhesive)
Number of subjects: 60
Study 33774192 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 % sodium hypochlorite (NaOCl) with conventional cementation system (etch‐and‐rinse adhesive)
Number of subjects: 60
Study 33774192 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 % sodium hypochlorite (NaOCl) agitated by passive ultrasonic irrigation (PUI) with conventional cementation system (etch‐and‐rinse adhesive)
Number of subjects: 60
Study 33774192 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution with conventional cementation system (universal adhesive)
Number of subjects: 60
Study 33774192 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 % sodium hypochlorite (NaOCl) with conventional cementation system (universal adhesive)
Number of subjects: 60
Study 33774192 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 % sodium hypochlorite (NaOCl) agitated by passive ultrasonic irrigation (PUI) with conventional cementation system (universal adhesive)
Number of subjects: 60
Study 34086911 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (RYGB)
Number of subjects: 13
Study 33832816 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndesmosis transfixation with a screw (13 patients)
Number of subjects: 24
Study 33832816 — intervention group
Group type: COMPARATOR
Intervention: No fixation (11 patients)
Number of subjects: 24
Study 33832816 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndesmosis transfixation with a screw
Number of subjects: 24
Study 33832816 — intervention group
Group type: COMPARATOR
Intervention: No fixation
Number of subjects: 24
Study 32044678 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention (PFI)
Number of subjects: 164
Study 32044678 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only controls
Number of subjects: 164
Study 33579804 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3
Number of subjects: 16
Study 33579804 — intervention group
Group type: COMPARATOR
Intervention: 68Ga-DOTA-LM3
Number of subjects: 16
Study 33579804 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3
Number of subjects: 16
Study 36169086 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 250 mg once daily for 3 days
Number of subjects: 128
Study 36169086 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 6 mg once daily for up to 10 days
Number of subjects: 128
Study 32207776 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and zinc supplementation
Number of subjects: 1503
Study 32207776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1503
Study 33882590 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of aspirin daily at bedtime
Number of subjects: 50
Study 33882590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35698432 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of laterality through implicit motor imagery
Number of subjects: 38
Study 35698432 — intervention group
Group type: COMPARATOR
Intervention: Recognition of body parts (Control)
Number of subjects: 38
Study 34189446 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus oral IVM at 0.6 mg/kg/day for 5 days
Number of subjects: 45
Study 34189446 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 45
Study 34670215 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab for all-RAS/quintuple-wildtype disease
Number of subjects: 40
Study 34670215 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab in case of RAS mutations
Number of subjects: 40
Study 32431208 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise group
Number of subjects: 60
Study 34857397 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1873
Study 34857397 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (three regimens)
Number of subjects: 1873
Study 34822113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant 35.6 mg/day
Number of subjects: 166
Study 34822113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 33115345 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Fuzzy Trees (GFT) system
Number of subjects: 43
Study 33115345 — intervention group
Group type: COMPARATOR
Intervention: Comparison to six common classification methods
Number of subjects: 43
Study 34014315 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified genes conferring salt tolerance from Tamarix hispida
Number of subjects: 1224
Study 616411777 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (1.25 mg/0.1 mL)
Number of subjects: 30
Study 616411777 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (0.02% for 3 minutes)
Number of subjects: 30
Study 36216089 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week cardiac rehabilitation program
Number of subjects: 80
Study 36216089 — intervention group
Group type: COMPARATOR
Intervention: Community-based exercise training
Number of subjects: 80
Study 33382926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg administered 30 min before a high-fat meal
Number of subjects: 12
Study 33382926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg administered 30 min after a high-fat meal
Number of subjects: 12
Study 33382926 — intervention group
Group type: COMPARATOR
Intervention: Tegoprazan 50 mg in fasting condition
Number of subjects: 12
Study 33382926 — intervention group
Group type: COMPARATOR
Intervention: Tegoprazan 50 mg administered in fasting condition
Number of subjects: 12
Study 35213105 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 80 μg plus usual care
Number of subjects: 1201
Study 35213105 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1201
Study 34002944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) with neoadjuvant chemotherapy
Number of subjects: 52
Study 34002944 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy without HCQ (control group)
Number of subjects: 52
Study 32465510 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 24
Study 32465510 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (CTR)
Number of subjects: 24
Study 35505367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-remifentanil (D-R)
Number of subjects: 59
Study 35505367 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil (P-R)
Number of subjects: 59
Study 33358843 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA‐120 (40 mg/kg/day DHA and 80 mg/kg/day ARA)
Number of subjects: 30
Study 33358843 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA‐360 (120 mg/kg/day DHA and 240 mg/kg/day ARA)
Number of subjects: 30
Study 33358843 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (placebo control)
Number of subjects: 30
Study 36326825 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate continuous glucose monitoring (CGM)
Number of subjects: 52
Study 36326825 — intervention group
Group type: COMPARATOR
Intervention: Stepped-care group (HypoAware followed by CGM if needed)
Number of subjects: 52
Study 33176850 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (4 ml, equivalent to 100 mg, administered into the trachea in two doses, starting on the day of intubation with a second dose 6 hours later)
Number of subjects: 60
Study 33176850 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (same volume based on weight, administered into the trachea with the same time schedule)
Number of subjects: 60
Study 35947315 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low‐level laser (LLL) therapy, 12 sessions
Number of subjects: 20
Study 35947315 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equipment without laser)
Number of subjects: 20
Study 35947315 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low‐level laser (LLL) therapy
Number of subjects: 20
Study 35947315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (active LLL and placebo)
Number of subjects: 20
Study 35947315 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency audiometry and acuphenometry outcomes
Number of subjects: 20
Study 34009725 — intervention group
Group type: EXPERIMENTAL
Intervention: DBLG1 closed-loop system
Number of subjects: 56
Study 32842812 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine/L-citrulline (5 g/day)
Number of subjects: 269
Study 32842812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 33491528 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 200 IU, Silymarin 750 mg, and l-carnitine 1 gram (VSC) for 18 weeks
Number of subjects: 0
Study 33491528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33645176 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (CT)
Number of subjects: 211
Study 33645176 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (TRT)
Number of subjects: 211
Study 33023661 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg plus MTX
Number of subjects: 328
Study 33023661 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg plus MTX
Number of subjects: 328
Study 33023661 — intervention group
Group type: COMPARATOR
Intervention: MTX plus placebo
Number of subjects: 328
Study 33023661 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg plus MTX and CZP 400 mg plus MTX
Number of subjects: 328
Study 35402691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (UH) 50 IU/kg bolus during the procedure
Number of subjects: 89
Study 35402691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 33714509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training for 12 weeks
Number of subjects: 30
Study 33714509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 33092617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin-pulp biostimulation chitosan membrane (BBio group)
Number of subjects: 468
Study 33092617 — intervention group
Group type: COMPARATOR
Intervention: Mineral trioxide aggregate (control group)
Number of subjects: 468
Study 34247667 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS intervention
Number of subjects: 82
Study 34247667 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 82
Study 33947255 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate (0.1 mg) administered on the day of embryo transfer along with routine luteal support
Number of subjects: 893
Study 33947255 — intervention group
Group type: COMPARATOR
Intervention: Luteal support only
Number of subjects: 893
Study 32291596 — intervention group
Group type: EXPERIMENTAL
Intervention: Value for money analyses in non-randomised studies
Number of subjects: 0
Study 32291596 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0
Study 35603600 — intervention group
Group type: COMPARATOR
Intervention: Metformin 850 mg twice daily
Number of subjects: 3234
Study 35603600 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle intervention
Number of subjects: 3234
Study 35603600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 35603600 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234
Study 35603600 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 3234
Study 35735452 — intervention group
Group type: EXPERIMENTAL
Intervention: True North Peer Navigation (PN) program
Number of subjects: 145
Study 32415721 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT condition (n=354)
Number of subjects: 718
Study 32415721 — intervention group
Group type: COMPARATOR
Intervention: Health education condition (n=364)
Number of subjects: 718
Study 35804452 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (2 cycles every 3 weeks)
Number of subjects: 60
Study 35804452 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (As2O3) and carboplatin (2 cycles every 3 weeks)
Number of subjects: 60
Study 33801251 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine at a dose of 9 mg/kg body mass
Number of subjects: 40
Study 33801251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32702849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusu mixture combined with Western medicine
Number of subjects: 620
Study 32702849 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment group
Number of subjects: 620